TCGA-CV-5966-01A-11R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.124429224
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.700
- INTERFERON_ALPHA_RESPONSE+0.660
- MYC_TARGETS_V1+0.640
- E2F_TARGETS+0.630
- DNA_REPAIR+0.530
- INTERFERON_GAMMA_RESPONSE+0.530
- G2M_CHECKPOINT+0.480
- OXIDATIVE_PHOSPHORYLATION+0.410
- ALLOGRAFT_REJECTION+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.360
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.370
- KRAS_SIGNALING_DN-0.310
- BILE_ACID_METABOLISM-0.260
- HYPOXIA-0.260
- ESTROGEN_RESPONSE_EARLY-0.240
- UV_RESPONSE_DN-0.230
- APICAL_SURFACE-0.160
- HEME_METABOLISM-0.150
- PROTEIN_SECRETION-0.120
- ESTROGEN_RESPONSE_LATE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-QK-A6IG-01A-11R-A31N-07 | — | — | 0.889 |
| 2 | SRR934927 | — | — | 0.887 |
| 3 | B1A2365C-5491-4E85-AE7E-97B9DB8FF8D1 | — | — | 0.883 |
| 4 | BS_QX12J6W1 | ATRT | — | 0.883 |
| 5 | E92DD0CC-DD0F-469D-8357-228A4A67DBD6 | — | — | 0.881 |
| 6 | 060C8F0B-DAB8-43DB-80C9-3404AFCC0B7D | — | — | 0.872 |
| 7 | 4EA4A8AE-581A-4170-8062-99645CB41337 | — | — | 0.870 |
| 8 | X29cb9797.16bb.49a5.bb14.fd9e9d48bbb4 | — | cohortA1 | 0.870 |
| 9 | D1729A17-148B-4C58-BEB5-7C4349A0E920 | — | — | 0.869 |
| 10 | 381221D6-D0E6-47B3-AB59-468AE2A5FC0A | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.700 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.660 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.640 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.530 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |